Roche Holding AG operates as a research based healthcare company. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the early detection, prevention, diagnosis, and treatment of diseases. Divisions The company operates primarily in two sectors: pharmaceuticals and diagnostics. Key pharmaceutical products are in oncology, anaemia, transplantation, virology, and rheumatoid arthritis. Roche's oncology portfolio includes five medicines for cancer. Pharmaceuticals Division's oncology portfolio includes a range of products, such as: MabThera/Rituxan, Herceptin, Avastin, Tarceva, Xeloda, NeoRecormon, Kytril, Neutrogin, Neupogen, Bondronat, Roferon-A, Furtulon, and Vesanoid. The Roche Group's anemia franchise includes three erythropoietin-stimulating agents (ESAs): Roche's Mircera (methoxy polyethylene glycol-epoetin beta), the continuous erythropoietin receptor activator, and the shorter-acting ESAs NeoRecormon and Epogin (epoetin beta), from Roche and Chugai, respectively. All three medicines are used to treat symptomatic anemia in patients with chronic kidney disease. In addition, NeoRecormon is approved to treat chemotherapy-induced anemia in cancer patients. Roche Professional Diagnostics (formerly Centralized Diagnostics and Near Patient Testing) supplies instrument systems, tests, software, workflow automation and services that help clinical laboratories deliver diagnostic results. It is also engaged in the market for decentralized testing products to support clinical decision-making close to the patient, in doctors' offices, intensive care units and other primary and specialty care settings. In December 2008 the company completed its acquisition of German-based Swisslab GmbH, a provider of laboratory information systems (LIS) and related services. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche's proprietary real-time polymerase chain reaction (PCR) technology. Roche Molecular Diagnostics' virology portfolio includes systems for automated sample preparation and real-time PCR analysis. In June 2008 Roche signed an exclusive deal with DxS Ltd. (U.K.) for distribution of the TheraScreen K-RAS Mutation Test. Roche Applied Science supplies various instruments and test reagents and test kits for use in this research market. Roche Applied Science offers placements of sequencing systems. Products are offered for real-time quantitative PCR (qPCR) analysis, particularly the LightCycler 480 instruments and reagents in North America and China. In September 2008 Roche Applied Science launched its GS FLX Titanium series of sequencing products (including new reagents and software). Other major launches included MagNa Pure 2.0, a redesigned and improved instrument for automated qPCR sample preparation, and the first of a new family of pre-plated, ready-to-use qPCR assays called RealTime ready. In 2008, Roche Applied Science launched single- and multi-plate versions of the xCELLigence cell analyser, a system co-developed with ACEA Biosciences, Inc. Roche Applied Science is also a supplier of industrial reagents and substrates, which account for a major part of its sales revenues. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In addition, the company offers premier workflow solutions designed to improve laboratory testing efficiency, providing automated safeguards to improve the quality of patient healthcare worldwide. Significant Events On June 8, 2009, Pontifax Ltd. has signed an agreement with Roche Holding AG to jointly invest in Israeli companies. Under the agreement, Roche would invest in incubator companies and Pontifax's existing companies. Later on, Pontifax would set up clusters, which would combine various companies in various sectors and in various stages of clinical trials, and Roche would invest alongside Pontifax in those entities. The company and Google Inc. have started a joint project to demonstrate the feasibility of developing a multidisciplinary surveillance, research, and response system. On September 2, 2009, PTC Therapeutics Inc. announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS). On October 29, 2009, Yissum Research Development Company Ltd. announced that it has signed a long-term multi-project research and license collaboration agreement with Roche Holding AG. In November 2009, Roche Holding AG would announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities. In November 2009, Alnylam Pharmaceuticals Inc. announced that it has advanced to the RNAi therapeutic collaboration stage of its alliance with Roche Holding AG formed in 2007. In this phase of the collaboration, the partners would jointly collaborate on the discovery and development of specific RNAi therapeutic products and each would contribute delivery technologies in the new disease target-focused effort. On January 11, 2010, Galapagos NV announced that it has entered into a global multi-year strategic alliance with Roche Holding AG to develop potential new therapies in COPD (chronic obstructive pulmonary disease). In the alliance, Galapagos would apply its target discovery platform to discover COPD targets. Galapagos is then responsible for the discovery and development of new small molecule candidate drugs against these targets. History Roche Holding AG was founded in 1896.
roche holding ag-br
(RO:SIX Swiss Exchange)
Phone: 41 61 688 11 11
Fax: 41 61 691 93 91www.roche.com
|Amgen Inc||$158.99 USD||+0.69|
|Bristol-Myers Squibb Co||$71.96 USD||-0.22|
|Gilead Sciences Inc||$89.00 USD||+0.79|
|Novartis AG||SFr.73.25 CHF||+0.05|
|Pfizer Inc||$32.80 USD||+0.09|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.